Apr. 19 2024

Found: WGS) in undiagnosed rare conditions ..................................................... 31 14.

S6W-27622

Asked by: Choudhury, Foysol (Scottish Labour - Lothian)

Question

To ask the Scottish Government what medical advice it had received, regarding any risks of blood clots, prior to its decision to suspend the use of the AstraZeneca COVID-19 vaccine for under-30s in April 2021.

Answered by Minto, Jenni - Minister for Public Health and Women's Health

The Scottish Government’s decision-making throughout all COVID-19 vaccination programmes has been guided by the expert clinical advice of both the Joint Committee on Vaccination and Immunisation (JCVI) and the Medicines and Healthcare products Regulatory Agency (MHRA).

Scotland has three representatives that attend the JCVI, including its COVID-19 committee and subcommittee; one co-opted member, an invited observer from Scottish Government and another invited observer from Public Health Scotland.

The MHRA’s pharmacovigilance process, alongside wider global data, identified reports of extremely rare adverse events of concurrent thrombosis and thrombocytopenia following vaccination with the first dose of the AstraZeneca Covid-19 vaccine.

As reports of extremely rare adverse event of concurrent thrombosis (blood clots) and thrombocytopenia (low platelet count) following vaccination with the first dose of the AstraZeneca (AZ) COVID-19 vaccine emerged in spring 2021, both the MHRA and the JCVI met to assess the data and the relative balance of benefits and risks.

The minutes from the JCVI COVID-19 Committee on 16 March 2021 and 18 March 2021 show that there was discussion of the topic and that the MHRA was working with international and European colleagues to share data and assess the risk.

The JCVI met again on the 6 April and on 7 April and published advice for the four UK health departments recommending that for adults aged under 30 years of age, without underlying health conditions that put them at higher risk of severe COVID-19 disease, there should be a preference for an alternative to the AstraZeneca vaccine, if available.

The following day on 8 April, Scotland’s Chief Medical Officer (CMO) issued a letter to the Scottish system stating the changes in the use of AstraZeneca vaccine and advising that Health Boards should now offer those under 30 years of age, without underlying health conditions, an alternative to the AstraZeneca vaccine. We also amended our patient information leaflets to reflect this new advice.